- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
18 result(s) found for: talimogene laherparepvec.
Displaying page 1 of 1.
EudraCT Number: 2014-001146-13 | Sponsor Protocol Number: 20110266 | Start Date*: 2015-01-15 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB... | |||||||||||||
Medical condition: Resectable, Stage IIIB to IVM1a Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003196-29 | Sponsor Protocol Number: 20120139 | Start Date*: 2018-02-07 |
Sponsor Name:Amgen Inc. | ||
Full Title: A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials | ||
Medical condition: Any tumor type eligible for treatment with talimogene laherparepvec in Amgen or BioVEX-sponsored clinical trial | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-005552-15 | Sponsor Protocol Number: 20120325 | Start Date*: 2015-05-18 |
Sponsor Name:Amgen Inc. | ||
Full Title: A Phase 2, Multicenter, Open-label, Single-arm Trial to Evaluate the Correlation Between Objective Response Rate and Baseline Immunoprofile Intratumoral CD8+ Cell Density in Subjects With Unresecte... | ||
Medical condition: Unresected stage IIIB to IVM1c melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) ES (Completed) DE (Completed) BE (Completed) AT (Completed) HU (Completed) PL (Completed) GR (Completed) NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002834-30 | Sponsor Protocol Number: 20120328 | Start Date*: 2015-07-14 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects in Europe With Unresected Stage IIIB to IVM1c Melanoma | |||||||||||||
Medical condition: Unresectable, Stage IIIB to IVM1c Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001906-61 | Sponsor Protocol Number: 20180115 | Start Date*: 2020-05-18 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: Phase 2 Study of Talimogene Laherparepvec in Combination With Pembrolizumab in Subjects With Unresectable/Metastatic Stage IIIB-IVM1d Melanoma Who Have Progressed on Prior Anti PD-1 Based Therapy | |||||||||||||
Medical condition: Unresectable/Metastatic Stage IIIB-IVM1d Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) GR (Completed) PL (Prematurely Ended) ES (Ongoing) FR (Prematurely Ended) GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000185-22 | Sponsor Protocol Number: 20110265 | Start Date*: 2014-12-03 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma | |||||||||||||
Medical condition: Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) ES (Prematurely Ended) BE (Completed) DE (Prematurely Ended) AT (Prematurely Ended) GR (Completed) IT (Prematurely Ended) FI (Prematurely Ended) CZ (Completed) PT (Completed) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003011-38 | Sponsor Protocol Number: 20130232 | Start Date*: 2016-02-29 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Phase 1b/3 Multicenter, Randomized, Trial of Talimogene Laherparepvec in combination with Pembrolizumab for theTreatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the He... | |||||||||||||
Medical condition: Metastatic Squamous Cell Carcinoma of the Head and Neck | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) AT (Completed) ES (Completed) GR (Completed) DE (Prematurely Ended) PT (Completed) FR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003645-25 | Sponsor Protocol Number: 20110261 | Start Date*: 2016-03-21 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects with Advanced Non Central Nervous SystemTumors Th... | |||||||||||||
Medical condition: Non-Central Nervous System (CNS) Tumors | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Completed) SE (Prematurely Ended) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000307-32 | Sponsor Protocol Number: 20110264 | Start Date*: 2014-11-18 |
Sponsor Name:Amgen Inc. | ||
Full Title: A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Me... | ||
Medical condition: Unresected, Stage IIIB-IV Melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-005386-67 | Sponsor Protocol Number: 20140318 | Start Date*: 2017-03-27 | ||||||||||||||||
Sponsor Name:Amgen Inc. | ||||||||||||||||||
Full Title: A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b an... | ||||||||||||||||||
Medical condition: Hepatocellular carcinoma (HCC) and metastatic liver tumors (non-HCC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) AT (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-004403-12 | Sponsor Protocol Number: APHP190871 | Start Date*: 2020-10-26 |
Sponsor Name:ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS | ||
Full Title: Phase II multicenter study of talimogene laherparepvec in classic or endemic Kaposi sarcoma Kapvec Study | ||
Medical condition: The study will provide an overview of efficacy and safety of talimogene laherparepvec in classic and endemic KS | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002165-19 | Sponsor Protocol Number: 20177308 | Start Date*: 2019-05-10 |
Sponsor Name:Medical University Vienna | ||
Full Title: Neo-BCC trial: Neoadjuvant treatment of difficult to resect, locally advanced basal cell carcinoma (BCC) with Talimogene laherparepvec (T-VEC) | ||
Medical condition: Basal cell carcinoma (BCC) is the most common malignant neoplasm in fair skinned humans (Rubin et al., 2005). Over the last decades its incidence has increased (Chinem and Miot, 2011). Especially w... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002677-22 | Sponsor Protocol Number: TVECUSDoppler | Start Date*: 2020-02-05 |
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | ||
Full Title: Doppler sonography of skin and nodal metastases as a predictor of clinical response to Talimogene Laherparepvec (T-VEC) in melanoma patients (T-VEC – US Doppler) | ||
Medical condition: Melanoma stage IIIB-IVM1a | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001911-22 | Sponsor Protocol Number: N19TVN | Start Date*: 2020-06-04 | |||||||||||||||||||||
Sponsor Name:Antoni van Leeuwenhoek Ziekenhuis | |||||||||||||||||||||||
Full Title: Neo-adjuvant T-VEC + NivolumabAnti-PD-1 combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease | |||||||||||||||||||||||
Medical condition: Patients with early metastatic (stage IIIB/C/D/IV M1a (AJCC 8)) melanoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000317-78 | Sponsor Protocol Number: PV-10-MM-31 | Start Date*: 2017-02-24 | |||||||||||
Sponsor Name:PROVECTUS BIOPHARMACEUTICALS, INC. | |||||||||||||
Full Title: PV-10 Intralesional Injection vs Systemic Chemotherapy or Intralesional Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma | |||||||||||||
Medical condition: Locally Advanced Cutaneous Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000873-26 | Sponsor Protocol Number: CLXH254C12201 | Start Date*: 2020-11-02 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: A randomized, open-label, multi-arm, two-part, phase II study to assess the efficacy and safety of multiple LXH254 combinations in patients with previously treated unresectable or metastatic BRAFV6... | ||||||||||||||||||
Medical condition: previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NO (Completed) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) FR (Trial now transitioned) AT (Completed) NL (Ongoing) PL (Completed) BE (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001557-31 | Sponsor Protocol Number: ALKS4230-006 | Start Date*: 2022-01-31 | |||||||||||
Sponsor Name:Alkermes, Inc. | |||||||||||||
Full Title: A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients Wi... | |||||||||||||
Medical condition: Advanced cutaneous melanoma and Advanced mucosal melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000505-80 | Sponsor Protocol Number: BT-001.01 | Start Date*: 2021-01-21 | |||||||||||
Sponsor Name:TRANSGENE | |||||||||||||
Full Title: A phase I/IIa study of intra-tumoral BT-001 (TG6030) administered alone and in combination with pembrolizumab in patients with cutaneous or, subcutaneous lesions or easily injectable lymph nodes of... | |||||||||||||
Medical condition: Phase I: Advanced or metastatic solid tumors including Non-Hodgkin Lymphoma (NHL) and preferably Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Smal Cell L... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
